Medtronic plc Medtronic plc

Medtronic plc

MDT

Peringkat dalam Saham #184
Medtronic plc is a leading global medical technology enterprise that invents,... Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Harga Saham
$94.59
Kapitalisasi Pasar
$120.99B
Perubahan (1 hari)
1.76%
Perubahan (1 tahun)
-1.39%
Negara
IE
Perdagangan Medtronic plc (MDT)

Kategori

Healthcare
Rasio P/E untuk Medtronic plc (MDT)
Rasio P/E per May 2026 TTM: 21.39
Menurut laporan keuangan dan harga saham terbaru dari Medtronic plc, rasio P/E saat ini (TTM) adalah 21.39. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 28.98.
Riwayat rasio P/E untuk Medtronic plc dari 2000 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
2026 (TTM) 21.39 -8.48%
2025 23.37 -19.35%
2024 28.98 -9.95%
2023 32.18 15.76%
2022 27.80 -43.06%
2021 48.83 75.64%
2020 27.80 9.46%
2019 25.40 -28.52%
2018 35.53 24.91%
2017 28.44 -9.80%
2016 31.53 -0.78%
2015 31.78 65.27%
2014 19.23 40.13%
2013 13.72 23.30%
2012 11.13 -23.39%
2011 14.53 -6.85%
2010 15.60 -5.77%
2009 16.55 -32.91%
2008 24.67 13.60%
2007 21.72 -8.07%
2006 23.62 -33.21%
2005 35.37 13.16%
2004 31.26 -13.97%
2003 36.33 -33.97%
2002 55.03 7.28%
2001 51.29 -9.73%
2000 56.83 0.00%
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
33.11 54.80%
US
28.94 35.33%
US
17.34 -18.93%
US
- -
DE
49.68 132.30%
US
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.